Sorafenib induced acral pigmentation: A new entity
Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoaca...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2015-04-01
|
| Series: | Avicenna Journal of Medicine |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.154199 |
| _version_ | 1818342738292113408 |
|---|---|
| author | Mrinal Gupta Heena Gupta Anish Gupta |
| author_facet | Mrinal Gupta Heena Gupta Anish Gupta |
| author_sort | Mrinal Gupta |
| collection | DOAJ |
| description | Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoacanthomas, squamous cell carcinomas and eruptive melanocytic naevi. We report a case of asymptomatic hyperpigmentation of the palms and soles in a patient receiving Sorafenib therapy for advanced renal cell carcinoma, in the absence of features of classic HFS, which has not been previously reported in the literature. |
| first_indexed | 2024-12-13T16:19:27Z |
| format | Article |
| id | doaj.art-fd80886f7a3142ab83d6f4136991577e |
| institution | Directory Open Access Journal |
| issn | 2231-0770 2249-4464 |
| language | English |
| last_indexed | 2024-12-13T16:19:27Z |
| publishDate | 2015-04-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Avicenna Journal of Medicine |
| spelling | doaj.art-fd80886f7a3142ab83d6f4136991577e2022-12-21T23:38:46ZengThieme Medical and Scientific Publishers Pvt. Ltd.Avicenna Journal of Medicine2231-07702249-44642015-04-010502464810.4103/2231-0770.154199Sorafenib induced acral pigmentation: A new entityMrinal Gupta0Heena Gupta1Anish Gupta2Sudhaa Skin Centre, Jammu, Jammu and Kashmir, IndiaSudhaa Skin Centre, Jammu, Jammu and Kashmir, IndiaSudhaa Skin Centre, Jammu, Jammu and Kashmir, IndiaSorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoacanthomas, squamous cell carcinomas and eruptive melanocytic naevi. We report a case of asymptomatic hyperpigmentation of the palms and soles in a patient receiving Sorafenib therapy for advanced renal cell carcinoma, in the absence of features of classic HFS, which has not been previously reported in the literature.http://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.154199acral pigmentationhand foot syndromesorafenib |
| spellingShingle | Mrinal Gupta Heena Gupta Anish Gupta Sorafenib induced acral pigmentation: A new entity Avicenna Journal of Medicine acral pigmentation hand foot syndrome sorafenib |
| title | Sorafenib induced acral pigmentation: A new entity |
| title_full | Sorafenib induced acral pigmentation: A new entity |
| title_fullStr | Sorafenib induced acral pigmentation: A new entity |
| title_full_unstemmed | Sorafenib induced acral pigmentation: A new entity |
| title_short | Sorafenib induced acral pigmentation: A new entity |
| title_sort | sorafenib induced acral pigmentation a new entity |
| topic | acral pigmentation hand foot syndrome sorafenib |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.154199 |
| work_keys_str_mv | AT mrinalgupta sorafenibinducedacralpigmentationanewentity AT heenagupta sorafenibinducedacralpigmentationanewentity AT anishgupta sorafenibinducedacralpigmentationanewentity |